Do we need thrombin generation assays for monitoring anticoagulation?

Thrombosis and Haemostasis

Volumn 100, Issue 2, 2008, Pages 179-180

  Dempfle, Carl Erik ^a   Borggrefe, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ANTICOAGULATION; ASSAY; BIOLOGICAL MONITORING; BLEEDING; DRUG EFFECT; DRUG HALF LIFE; EDITORIAL; HUMAN; KIDNEY DYSFUNCTION; PRIORITY JOURNAL; THROMBOPLASTIN TIME;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; DRUG MONITORING; HUMANS; THROMBIN;

EID: 48949097645     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-07-0437     Document Type: Editorial

References (14)

1. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
2. Makris M, Hough RE, Kitchen S. Poor reversal of low molecular weight heparin by protamine. Br J Haematol 2000; 108: 884-885.
3. Gatt A, van Veen JJ, Woolley AM, et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-355.
4. Wolzt M, Weltermann A, Nieszpaur-Los M, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995; 73: 439-443.
5. Holst J, Lindblad B, Bergqvist D, et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis 1994; 5: 795-803.
6. Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 2007; 13: 409-413.
7. Brophy DF, Martin EJ, Gehr TW, et al. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006; 4: 372-376.
8. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
9. Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 1: 2368-2373.
10. Young G, Yonekawa KE, Nakagawa PA, et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007; 18: 547-553.
11. Brophy DF, Carr ME, Jr., Martin EJ, et al. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. J Clin Pharmacol 2006; 46: 887-894.
12. Gerotziafas GT, Depasse F, Chakroun T, et al. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis 2004; 15: 149-156.
13. Gerotziafas GT, Petropoulou AD, Verdy E, et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-962.
14. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-888.